Bicycle Therapeutics plc American Depositary Shares (BCYC) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with BCYC
Recent news

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
BCYC

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
BCYC

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
BCYC

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
BCYC
Technical indicators
- RSI 14
- 44.65
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.02
- SMA 50
- $3.94
- Price below SMA 50
- EMA 50
- $3.90
- Price below EMA 50
- SMA 200
- $4.76
- Price below SMA 200
- EMA 200
- $4.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
BCYC

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
BCYC

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
BCYC

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
BCYC

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
BCYC

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
BCYC

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)
BCYC

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
BCYC

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
BCYC

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
BCYC
About Bicycle Therapeutics plc American Depositary Shares
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Executive Director | 1968 |
| Mr. Travis Thompson | Chief Financial Officer | 1980 |
| Dr. Jennifer Perry Pharm.D. | Chief Operating Officer | 1974 |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Alistair Milnes | Chief Corporate Development Officer | 1974 |
| Dr. Christian Heinis | Scientific Founder | — |
| Ms. Stephanie Yao | Senior Vice President of Investor Relations and Corporate Communications | — |
| Mr. Zafar Qadir | Chief Legal Officer & General Counsel | — |
| Dr. Phil Jeffrey | Senior VP of Pre-Clinical Development | — |
| Dr. Michael Charles-Ferguson Hannay | Chief Product & Supply Chain Officer | 1966 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 44.65
- MACD 12/26/9
- -0.05
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.02
- SMA 50
- $3.94
- Price below SMA 50
- EMA 50
- $3.90
- Price below EMA 50
- SMA 200
- $4.76
- Price below SMA 200
- EMA 200
- $4.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $14.00
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.5 | -3.7 | -2.3 | -6.4 | -8.3 | +6.7 | -10.2 | +6.7 |



